Physician profile
Sidney A Jones
NPI 1508806811
$66,522.67
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $9,420 · 2021: $15K · 2022: $2,149 · 2023: $20.05 · 2024: $69.86 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $210.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44,944.71 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $8,666.83 | 2019-2024 | |
| Lilly USA, LLC | $8,407.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,058.31 | 2019 | |
| Intuity Medical INC | $117.84 | 2022 | |
| Sequel Med Tech, LLC | $70.08 | 2025 | Twiist |
| Novo Nordisk INC | $65.63 | 2019 | |
| Beta Bionics, INC. | $44.25 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $37.93 | 2023-2025 | Dexcom G6 Transmitter |
| Senseonics, Incorporated | $23.00 | 2019 | |
| Cequr Corporation | $19.75 | 2022 | |
| Amgen INC. | $18.64 | 2024 | Tepezza |
| Abbott Laboratories | $17.96 | 2019 | |
| Pfizer INC. | $16.54 | 2025 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.